Hyperlipidemia is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hyperlipidemia have a 93.75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hyperlipidemia compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hyperlipidemia overview
Hyperlipidemia is a medical condition characterized by elevated levels of lipids (fats) in the blood. This includes high levels of cholesterol and triglycerides. It is a significant risk factor for cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hyperlipidemia can be caused by genetic factors, an unhealthy diet high in saturated fats and cholesterol, sedentary lifestyle, obesity, and certain medical conditions like diabetes mellitus. Diagnosis is typically made through blood tests measuring lipid levels. Treatment involves lifestyle modifications such as a healthy diet, regular exercise, and weight management. Medications, including statins, may be prescribed to lower lipid levels and reduce cardiovascular risk. Regular monitoring is essential for managing hyperlipidemia effectively.
For a complete picture of PTSR and LoA scores for drugs in Hyperlipidemia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
